14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
KMTS vs DXR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). KMTS carries a Unified Composite Score of 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin).
Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -5894.3% operating margin) and revenue trajectory (+59.9% vs. +25.5% YoY).
Technical & Structure Timing Caution: KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KMTS vs DXR. Trailing 12-month operating profitability (KMTS -134.5% vs DXR -5894.3%) and valuation multiples (KMTS N/M vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KMTS vs DXR Key Questions & Quantitative Answers
As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). KMTS carries a Unified Composite Score of 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -5894.3% operating margin) and revenue trajectory (+59.9% vs. +25.5% YoY). Technical & Structure Timing Caution: KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KMTS leads the Growth & Scale pillar: KMTS posts +59.9% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (53.9% gross margin, -134.5% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, KMTS generates $107M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, KMTS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.
DXR screens cheaper on headline valuation multiples. KMTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.5x EV/Revenue (-109.7% FCF margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KMTS (-73.7% ROE) versus DXR (14.2% ROE) capital efficiency.
In options market volatility and institutional positioning, KMTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 63% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.